{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:54:10Z","timestamp":1793778850862,"version":"4.6.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bioorg.2026.109789","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:10:40Z","timestamp":1774311040000},"page":"109789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Design, synthesis, and mechanistic study of bispecific small molecules-based phenyl pyrazolopyrimidinone scaffold as dual-targeting VEGFR and PD-L1 immune checkpoint in hepatocellular carcinoma"],"prefix":"10.1016","volume":"175","author":[{"given":"Esraa.M.M.","family":"Hassoub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahgat R.M.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamdouh F.A.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El-Shimaa M.N.","family":"Abdelhafez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bioorg.2026.109789_bb0005","doi-asserted-by":"crossref","first-page":"300","DOI":"10.17998\/jlc.2023.08.27","article-title":"Management of early-stage hepatocellular carcinoma: challenges and strategies for optimal outcomes","volume":"23","author":"Yoon","year":"2023","journal-title":"JLC"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109789_bb0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.17998\/jlc.2021.09.24","article-title":"Advances in immune checkpoint inhibitors for hepatocellular carcinoma","volume":"21","author":"Han","year":"2021","journal-title":"J Liver Cancer."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109789_bb0015","first-page":"568","article-title":"Anti-PD-1\/L1 antibody plus anti-VEGF antibody vs. plus VEGFR-targeted TKI as first-line therapy for unresectable hepatocellular carcinoma: a network meta-analysis. Exploration of targeted anti-tumor","volume":"5","author":"Zhou","year":"2024","journal-title":"Therapy"},{"key":"10.1016\/j.bioorg.2026.109789_bb0020","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nutres.2024.06.010","article-title":"Vascular endothelial growth factor is associated with hepatocellular carcinoma recurrence, independent of folate and glutathione-related antioxidant enzymes: a follow-up study","volume":"128","author":"Hsiao","year":"2024","journal-title":"Nutr. Res."},{"key":"10.1016\/j.bioorg.2026.109789_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108023","article-title":"Exploring a novel thiazole derivatives hybrid with fluorinated-indenoquinoxaline as dual inhibitors targeting VEGFR2\/AKT and apoptosis inducers against hepatocellular carcinoma with docking simulation","volume":"154","author":"Abusaif","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109789_bb0030","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2214\/ajr.183.6.01831585","article-title":"Expression of vascular endothelial growth factor in hepatocellular carcinoma and the surrounding liver: correlation with angiographically assisted CT","volume":"183","author":"Kanematsu","year":"2004","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.bioorg.2026.109789_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1070961","article-title":"PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109789_bb0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed Death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109789_bb0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40364-023-00535-z","article-title":"Biomarkers and prognostic factors of PD-1\/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma","volume":"12","author":"Zhang","year":"2024","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109789_bb0050","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s10753-021-01547-3","article-title":"Interferon gamma-induced interferon regulatory factor 1 activates transcription of HHLA2 and induces immune escape of hepatocellular carcinoma cells","volume":"45","author":"Wang","year":"2022","journal-title":"Inflammation"},{"key":"10.1016\/j.bioorg.2026.109789_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104352","article-title":"Design and synthesis of novel pyrazolo[3,4-d]pyrimidin-4-one bearing quinoline scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy","volume":"105","author":"Ibrahim","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109789_bb0060","first-page":"483","article-title":"Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia","volume":"39","author":"Parmar","year":"2014","journal-title":"Pharmacy and Therapeutics"},{"issue":"10","key":"10.1016\/j.bioorg.2026.109789_bb0065","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent- front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"issue":"22","key":"10.1016\/j.bioorg.2026.109789_bb0070","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib is a novel irreversible FGFR 1\u20134 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109789_bb0075","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/cancers12051089","article-title":"Scientific rationale for combined immunotherapy with PD-1\/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma","volume":"12","author":"Kudo","year":"2020","journal-title":"Cancers"},{"issue":"20","key":"10.1016\/j.bioorg.2026.109789_bb0080","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"16_suppl","key":"10.1016\/j.bioorg.2026.109789_bb0085","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1200\/JCO.2023.41.16_suppl.2589","article-title":"Safety and efficacy of HB0025, an anti-PD-1\/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: preliminary results from an FIH trial","volume":"41","author":"Du","year":"2023","journal-title":"JCO"},{"issue":"8","key":"10.1016\/j.bioorg.2026.109789_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28083491","article-title":"Novel PD-L1-targeted phenyl-Pyrazolone derivatives with antioxidant properties","volume":"28","author":"Regnault","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109789_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115468","article-title":"Design, synthesis, and evaluation of PD-1\/PD-L1 small-molecule inhibitors bearing a rigid indane scaffold","volume":"256","author":"Cai","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109789_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/ph18091326","article-title":"Design, synthesis, in silico docking, multitarget bioevaluation and molecular dynamic simulation of novel pyrazolo[3,4-d]pyrimidinone derivatives as potential in vitro and in vivo anti-inflammatory agents","volume":"18","author":"Roshdi","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2026.109789_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108181","article-title":"Exploration of anti-inflammatory activity of pyrazolo[3,4-d]pyrimidine\/1,2,4-oxadiazole hybrids as COX-2, 5-LOX and NO release inhibitors: design, synthesis, in silico and in vivo studies","volume":"156","author":"Aziz","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109789_bb0110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13765-023-00780-8","article-title":"Some novel peptides containing a modified pyrazolopyrimidine moiety: design, synthesis, and in vitro antibacterial screening","volume":"66","author":"Al-Mohammadi","year":"2023","journal-title":"Appl. Biol. Chem."},{"issue":"W1","key":"10.1016\/j.bioorg.2026.109789_bb0115","doi-asserted-by":"crossref","first-page":"W271","DOI":"10.1093\/nar\/gku339","article-title":"iMODS: internal coordinates normal mode analysis server","volume":"42","author":"L\u00f3pez-Blanco","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2026.109789_bb0120","series-title":"MTT Assay Protocol v1","author":"Hameed Abd","year":"2023"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109789_bb0125","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3390\/pharmaceutics12060595","article-title":"Quantification of pharmacokinetic profiles of PD-1\/PD-L1 antibodies by validated ELISAs","volume":"12","author":"Zalba","year":"2020","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.bioorg.2026.109789_bb0130","article-title":"The relationship between the Bcl-2\/Bax proteins and the mitochondria-mediated apoptosis pathway in the differentiation of adipose-derived stromal cells into neurons","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109789_bb0135","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol. Pathol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109789_bb0140","doi-asserted-by":"crossref","first-page":"64","DOI":"10.21608\/odr.2024.287410.1041","article-title":"A novel approach for apoptosis and caspase-3 inhibition using new candidates of 1,5-diaryl triazole-3-carboxamides","volume":"5","author":"Abdelhakem","year":"2024","journal-title":"Octahedron Drug Res."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109789_bb0145","doi-asserted-by":"crossref","first-page":"601","DOI":"10.4155\/fmc-2023-0336","article-title":"Design, synthesis and mechanistic study of new dual targeting HDAC\/tubulin inhibitors","volume":"16","author":"El-Zoghbi","year":"2024","journal-title":"Future Med. Chem."},{"issue":"21","key":"10.1016\/j.bioorg.2026.109789_bb0150","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1080\/17568919.2024.2394018","article-title":"One-pot synthesis and pharmacological evaluation of new quinoline\/pyrimido-diazepines as pulmonary antifibrotic agents","volume":"16","author":"Fawzy","year":"2024","journal-title":"Future Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109789_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202400470","article-title":"A review of recent advances in anticancer activity and SAR of pyrazole derivatives","volume":"358","author":"Hofny","year":"2025","journal-title":"Arch. Pharm."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109789_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/ph17050659","article-title":"Discovery and anticancer screening of novel oxindole-based derivative bearing pyridyl group as potent and selective dual FLT3\/CDK2 kinase inhibitor","volume":"17","author":"Soudi","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109789_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29020446","article-title":"Benzimidazole-based derivatives as apoptotic antiproliferative agents: design, synthesis, docking, and mechanistic studies","volume":"29","author":"Youssif","year":"2024","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.bioorg.2026.109789_bb0170","first-page":"91","article-title":"Comparative docking studies of estrogen receptor inhibitors and their binding interaction analysis","volume":"16","author":"Desai","year":"2012","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109789_bb0175","doi-asserted-by":"crossref","first-page":"22845","DOI":"10.3390\/ijms141122845","article-title":"Identification of novel small molecules as inhibitors of hepatitis C virus by structure-based virtual screening","volume":"14","author":"Li","year":"2013","journal-title":"IJMS"}],"updated-by":[{"DOI":"10.1016\/j.bioorg.2026.109830","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000}},{"DOI":"10.1016\/j.bioorg.2026.109830","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000}}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826003251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826003251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T13:23:37Z","timestamp":1775913817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826003251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":35,"alternative-id":["S0045206826003251"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109789","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and mechanistic study of bispecific small molecules-based phenyl pyrazolopyrimidinone scaffold as dual-targeting VEGFR and PD-L1 immune checkpoint in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109789","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109789"}}